News
Important Only
Kratos Issues Letter Of Intent For 60 Full Rate Production Zeus Hypersonic System Rocket Motors From L3harris
Dec 23 (Reuters) - Kratos Defense and Security Solutions Inc KTOS.O:KRATOS ISSUES LETTER OF INTENT FOR 60 FULL RATE PRODUCTION ZEUS HYPERSONIC SYSTEM ROCKET MOTORS FROM L3HARRISReuters
Tue, Dec 23
Coopercompanies Appoints Walter M Rosebrough, Jr. To Its Board Of Directors
Dec 23 (Reuters) - Cooper Companies Inc COO.O:COOPERCOMPANIES APPOINTS WALTER M ROSEBROUGH, JR. TO ITS BOARD OF DIRECTORSCOOPER COMPANIES INC - BOARD TO CONSIDER ROSEBROUGH FOR CHAIR BY END OF 2026COOPER COMPANIES INC - COOPERCOMPANIES ENTERS COOPERATION AGREEMENT WITH BROWNING WESTCOOPER COMPANIES ...Reuters
Tue, Dec 23
Coya Therapeutics Receives Clinical Trial Application Acceptance From Health Canada
Dec 23 (Reuters) - Coya Therapeutics Inc COYA.O:COYA THERAPEUTICS RECEIVES CLINICAL TRIAL APPLICATION (CTA) ACCEPTANCE FROM HEALTH CANADA TO PROCEED WITH THE COYA 302 ALSTARS TRIAL FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)COYA THERAPEUTICS INC - ALSTARS TRIAL UNDERWAY IN US AND CANADAReuters
Tue, Dec 23
CANADA RESEARCH ROUNDUP-Enbridge, Strathcona Resources, WSP Global
Dec 23 (Reuters) - Securities analysts revised their ratings and price targets on several Canadian companies, including Enbridge, Strathcona Resources and WSP Global, on Tuesday. HIGHLIGHTS Enbridge Inc ENB.TO: Jefferies cuts target price to C$71 from C$73 Strathcona Resources Ltd SCR.TO: A...Reuters
Tue, Dec 23
Reviva Announces Regulatory Update Regarding The Development Of Brilaroxazine For The Treatment Of Schizophrenia
Dec 23 (Reuters) - Reviva Pharmaceuticals Holdings Inc RVPH.O:REVIVA ANNOUNCES REGULATORY UPDATE REGARDING THE DEVELOPMENT OF BRILAROXAZINE FOR THE TREATMENT OF SCHIZOPHRENIAREVIVA PHARMACEUTICALS HOLDINGS INC - FDA RECOMMENDS SECOND PHASE 3 TRIAL FOR BRILAROXAZINEREVIVA PHARMACEUTICALS HOLDINGS INC...Reuters
Tue, Dec 23
Profound Medical Closes $36 Million Registered Direct Offering Expects To Complete Subsequent Private Placement On Or Before December 30Th
Dec 23 (Reuters) - Profound Medical Corp PRN.TO:PROFOUND MEDICAL CORP. CLOSES $36 MILLION REGISTERED DIRECT OFFERING; EXPECTS TO COMPLETE SUBSEQUENT PRIVATE PLACEMENT ON OR BEFORE DECEMBER 30THReuters
Tue, Dec 23
Israeli government has no intention of establishing settlements in Gaza, defence minister says
DUBAI, Dec 23 (Reuters) - The Israeli government has no intention of establishing settlements in Gaza, the country's Defence Minister Israel Katz said in a statement on Tuesday. Katz said earlier on Tuesday that the military would never fully withdraw from the Gaza Strip for security reasons and...Reuters
Tue, Dec 23
New Era Energy & Digital Secures Full Ownership Of Texas Critical Data Centers Through Binding Agreement
Dec 23 (Reuters) - New Era Energy & Digital Inc NUAI.O:NEW ERA ENERGY & DIGITAL SECURES FULL OWNERSHIP OF TEXAS CRITICAL DATA CENTERS THROUGH BINDING AGREEMENT, COMPLETES 203-ACRE LAND ACQUISITION EXPANDING TCDC CAMPUS IN ECTOR COUNTY, TEXASNEW ERA ENERGY & DIGITAL INC - HAS ENTERED INTO...Reuters
Tue, Dec 23
Wheels Up Advances Fleet Modernization Plan With Strategic Sale-Leaseback Transaction And Satellite Wi-Fi Milestone
Dec 23 (Reuters) - Wheels Up Experience Inc UP.N:WHEELS UP ADVANCES FLEET MODERNIZATION PLAN WITH STRATEGIC SALE-LEASEBACK TRANSACTION AND SATELLITE WI-FI MILESTONEWHEELS UP EXPERIENCE INC - SALE PRICE ABOUT $105 MILLION, $65 MILLION TO REPAY DEBTReuters
Tue, Dec 23
Mulberry Industries, Ramaco Resources Announce The Entry Into A Non-Binding Memorandum Of Understanding
Dec 23 (Reuters) - Ramaco Resources Inc METC.O:MULBERRY INDUSTRIES, RAMACO RESOURCES ANNOUNCE THE ENTRY INTO A NON-BINDING MEMORANDUM OF UNDERSTANDING THAT AIMS TO STRENGTHEN DOMESTIC RARE EARTH & PERMANENT MAGNET SUPPLY CHAINReuters
Tue, Dec 23
Immuneering To Announce 12-Month Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + mGnP
Dec 23 (Reuters) - Immuneering Corp IMRX.O:IMMUNEERING TO ANNOUNCE 12-MONTH OVERALL SURVIVAL DATA FROM PHASE 2A CLINICAL TRIAL OF ATEBIMETINIB + MGNP IN FIRST-LINE PANCREATIC CANCER PATIENTS ON JANUARY 7, 2026Reuters
Tue, Dec 23
